Hepatic Impairment Study for Lorlatinib in Cancer Patients

  • End date
    Apr 26, 2023
  • participants needed
  • sponsor
Updated on 25 September 2021


This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.


This will be a Phase 1, open label, multi center, multiple dose, non randomized, Phase 1 clinical trial of lorlatinib in advanced cancer patients with varying degrees of hepatic impairment and necessary age , weight , and gender matched prospect normal hepatic function patients. This study is intended to evaluate the potential effect of hepatic impairments on the PK and safety of lorlatinib after daily administration of lorlatinib and to provide dosing recommendation for patients with varied degree of hepatic impairment if possible.

Patients in the study will be assigned to different groups (A1, normal liver function, control for group B; A2, normal liver function, control for group C; B, mild hepatic impairment; C, moderate hepatic impairment; D, severe hepatic impairment) according to their liver function. The enrollment of approximately 76 advanced cancer patients is anticipated in this study in order to have 8 PK-evaluable patients in each of Groups A1, A2, B and C, and 6 PK-evaluable patients in Group D for final statistical analysis. Evaluable patients are those who complete the planned PK sample collection on Cycle 2 Day 1 and have no lorlatinib dose modification until completion of Cycle 2 Day 1 PK evaluation. Patients who are not evaluable for PK will be replaced. Each patient will be treated with repeated oral once daily doses of lorlatinib in 21-day cycles until disease progression, patient refusal, or unacceptable toxicity occurs. The dose schedule may be modified as necessary for individual patients according to tolerability.

Condition Advanced Cancers
Treatment Lorlatinib
Clinical Study IdentifierNCT03726333
Last Modified on25 September 2021


Yes No Not Sure

Inclusion Criteria

Histologically or cytologically confirmed solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective
Biliary obstruction with a biliary drain or stent
Neurologically stable gliomas and brain metastases
ECOG performance status of 0, 1, or 2
adequate bone marrow function
adequate pancreatic function
adequate renal function
female patients with negative pregnancy test

Exclusion Criteria

untreated esophageal varices; uncontrolled ascites
episodes of hepatic encephalopathy within the last 4 weeks
spinal cord compression; major surgery within 4 weeks prior to enrollment
radiation therapy within 2 weeks prior to enrollment
last anti-cancer treatment within 2 weeks prior to screening
previous high-dose chemotherapy requiring stem cell rescue
prior to irradiation to >25% of the bone marrow
gastrointestinal abnormalities
known prior or suspected hypersensitivity to lorlatinib or lorlatinib tablet
clinically significant bacterial, fungal or viral infections for non-liver cancer patients
clinically significant cardiovascular disease
uncontrolled hypertension; acute pancreatitis with predisposing characteristics
history of grade 3 or 4 interstitial fibrosis or interstitial lung disease
active hemoelysis or evidence of biliary sepsis
prior major gastrointestinal surgery
concurrent use of known strong CYP3A inhibitors, inducers and P-gp substrates with a narrow therapeutic index
concurrent use of CYP3A substrates with narrow therapeutic indices
prior treatment with lorlatinib; active bleeding disorder
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note